Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novel Anticoagulants Need Blood Level Monitoring Measures, FDA’s Temple Says

Apr 20 2015

• By Sue Sutter

Related Content

BMJ’s <em>Pradaxa</em> Exposé Includes Wider Call For Monitoring Of All New Anticoagulants

Jul 24 2014

FDAer Eyes Improvements In Anticoagulant Trial Design

May 01 2012

<em>Eliquis</em> Approval Delayed By Fraud, Dispensing Errors In Pivotal Trial

Jun 18 2013

<i>Pradaxa</i> Review Shows FDA Doubts About The Power Of REMS To Change Prescribing Practices

Apr 01 2011

<em>Savaysa</em> A-Fib Data Led To Conflicting FDA Views On Dose, Population

Apr 20 2015

Related Companies

Orphan Disease Treatment Institute Co., Ltd.

Boehringer Ingelheim GmbH

Johnson & Johnson

Bayer AG

Bristol Myers Squibb Company

Pfizer Inc.

Additional Topics

United States BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window